4 June 2026

ASX ANNOUNCEMENT

Commercial Momentum, Execution and Market Access Update

Highlights:

- US distribution agreements and insurance coverage in Germany
- Letter of intent for 1,000 NextLevel devices with US$100,000 upfront
- Apple BCI integration in development with global release targeted Q3 2026
- Multiple customers for NeuroStrip with the AFL, NRL, Australian Institute of Sport, Ohio University and many others
- Japanese Stroke Lab study showed a 39% reduction in muscle overactivity using NeuroStrip application
- Insurance billing model established in the US

MELBOURNE Australia 4 June 2026: Control Bionics Limited (ASX: CBL) today reported continued commercial execution and pipeline advancement across its three core neurotechnology platforms, Assistive Technology, Neurotechnology Solutions and Platform and Medical Technology.

The presentation released to the ASX today outlines the progress CBL has made in engaging customers across each of the 3 commercial pillars.

The Company continues to expand its global Assistive Technology footprint through key commercial and reimbursement milestones.

Following the allocation of the E2513 HCPCS billing code in the US, Control Bionics executed a nationwide distribution agreement with Tobii Dynavox and PRC-Saltillo in January 2026.

In Europe, HMV insurance coverage in Germany in February 2026 establishes a funded market pathway.

Product expansion progressed with an April 2026 letter of intent for 1,000 NextLevel iOS-based communication devices, supporting a partner-led distribution model.

The NeuroTech Solutions division continued to advance commercial validation of its wearable sEMG platform, NeuroStrip. Structured evaluation programs are underway with elite sports organisations and clinical institutions, including AFL and NRL clubs, the Australian Institute of Sport, Ohio University and many others.

These programs support applications in athlete monitoring, rehabilitation, and return-to-play decision-making.

Clinical and commercial traction is further supported by outcomes from Stroke Lab (Japan) and the implementation of an insurance-reimbursed service model with Mountain Land Physical Therapy in the US.

The Company is also progressing next-generation software capabilities, with development of Apple BCI protocol integration underway with a global commercial release targeted for Q3 2026.

Control Bionics CEO and Managing Director, Jeremy Steele, said: *"The commercial progress across our platforms reflects the scalability of our neural interface technology beyond assistive communication. With established distribution partnerships, new reimbursed markets, and growing enterprise adoption, we are building a diversified global commercial platform."*

For further information, please contact:

Investors:

Jeremy Steele – CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley - Company Secretary
brettcrowley@controlbionics.com
For further information visit the website: https://www.controlbionics.com/

For Media enquiries:
Andrew Geddes
Seed Media
andrew@seedmedia.com.au
+61 008 677 734

About Control Bionics:

Control Bionics Limited is a medical technology company commercialising assistive communication and neurotechnology products for people living with paralysis, loss of speech and other complex movement limitations. The Company's technology enables users to control digital devices using neuroelectric signals, spatial movement and other accessible control methods. Its current products include the NeuroNode® and NeuroStrip® platforms, assistive communication devices and emerging technologies for rehabilitation, sports performance and physiological monitoring.

About NeuroNode:

Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

About NeuroStrip:

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Europe and Japan.